NccRCC ‘material expansion opportunity’ for Exelixis, says William Blair

After Exelixis (EXEL) announced initiation of the Phase III STELLAR-304 trial of zanzalintinib in combination with Bristol-Myers’ (BMY) Opdivo in frontline advanced non-clear cell renal cell carcinoma, or nccRCC, William Blair analyst Andy Hsieh said he believes that the nccRCC market represents a "material expansion opportunity" for the zanzalintinib franchise. He estimates the global market in nccRCC "to be north of $1 billion commercially," added Hsieh, who has an Outperform rating on Exelixis shares.